Attila Szendroi
Overview
Explore the profile of Attila Szendroi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
544
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Varadi M, Nagy N, Reis H, Hadaschik B, Niedworok C, Modos O, et al.
Cancer Med
. 2023 Jan;
12(7):9041-9054.
PMID: 36670542
Objective: Administration of targeted therapies provides a promising treatment strategy for urachal adenocarcinoma (UrC) or primary bladder adenocarcinoma (PBAC); however, the selection of appropriate drugs remains difficult. Here, we aimed...
2.
Budai B, Stollmayer R, Ronaszeki A, Kormendy B, Zsombor Z, Palotas L, et al.
Front Med (Lausanne)
. 2022 Oct;
9:974485.
PMID: 36314024
Introduction: This study aimed to construct a radiomics-based machine learning (ML) model for differentiation between non-clear cell and clear cell renal cell carcinomas (ccRCC) that is robust against institutional imaging...
3.
Szalay A, Molnar G, Kosa D, Kadasi L, Papp A, Toth Z, et al.
Orv Hetil
. 2022 Aug;
163(34):1362-1368.
PMID: 35988088
Even during normal pregnancy, significant morphological, functional and hemodynamic changes take place in the kidneys, resulting in a slightly increased proteinuria. However, an abnormal increase, especially if accompanied by hypertension...
4.
Huttl A, Korda D, Lenard M, Szendroi A, Rudas G, Kalina I, et al.
Orv Hetil
. 2020 Dec;
161(52):2188-2194.
PMID: 33361504
Introduction: The past decade has seen some major changes in the diagnostics of prostate cancer. Progress in MR imaging has allowed us to better visualise prostate cancer and thus perform...
5.
Olah C, Tschirdewahn S, Hoffmann M, Krafft U, Hadaschik B, Nyirady P, et al.
Diagnostics (Basel)
. 2020 Oct;
10(11).
PMID: 33114033
Cisplatin-containing chemotherapy represents the first-line treatment for patients with locally advanced or metastatic muscle-invasive bladder cancer. Recently, novel therapies have become available for cisplatin-ineligible or -resistant patients. Therefore, prediction of...
6.
Nagy N, Reis H, Hadaschik B, Niedworok C, Modos O, Szendroi A, et al.
Pathol Oncol Res
. 2020 Aug;
26(4):2773-2781.
PMID: 32754865
Urachal carcinoma (UrC) is a rare tumor with remarkable histological and molecular similarities to colorectal cancer (CRC). Adenomatous polyposis coli (APC) is the most frequently affected gene in CRC, but...
7.
Kocsmar I, Pajor G, Gyongyosi B, Szekely E, Varga M, Kocsmar E, et al.
Am J Clin Pathol
. 2019 Nov;
153(2):274-284.
PMID: 31732739
Objectives: Our aim was to predict progression of non-muscle-invasive bladder urothelial carcinomas (NMIUCs) into muscle-invasive disease by assessing cytogenetic abnormality of tumors with a new UroVysion scoring system. Methods: Seventy-five...
8.
Krafft U, Tschirdewahn S, Hess J, Harke N, Hadaschik B, Olah C, et al.
Urol Oncol
. 2019 May;
37(11):810.e7-810.e15.
PMID: 31053526
Objectives: Cisplatin-based chemotherapy represents the gold standard in the treatment of advanced bladder cancer (BC) both in the neoadjuvant and adjuvant setting. Since novel immunooncologic agents are available for cisplatin-resistant...
9.
Reis H, van der Vos K, Niedworok C, Herold T, Modos O, Szendroi A, et al.
Int J Cancer
. 2018 Apr;
143(7):1764-1773.
PMID: 29672836
Urachal cancer (UrC) is a rare but aggressive malignancy often diagnosed in advanced stages requiring systemic treatment. Although cytotoxic chemotherapy is of limited effectiveness, prospective clinical studies can hardly be...
10.
Szendroi M, Antal I, Szendroi A, Lazary A, Varga P
EFORT Open Rev
. 2017 Oct;
2(9):372-381.
PMID: 29071122
Oncological management of skeletal metastases has changed dramatically in the last few decades. A significant number of patients survive for many years with their metastases.Surgeons are more active and the...